Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Inks Technology Evaluation Pact

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Accelr8 said that it has signed a technology evaluation agreement with an unnamed global diagnostic company for its BACcel system.

Accelr8 said that the deal includes an option to license the system and develop diagnostic products based on the technology. The firm said that it will receive an initial payment plus additional payments based on completion of data evaluation.

The BACcel system is a rapid bacterial diagnostics system that, according to the firm, can identify bacteria within two hours and their major resistance mechanisms within six hours. The firm has been working on tests for antibiotic resistance detection.

The system was at the center of an option agreement signed with Becton Dickinson in April 2008. However, last September BD declined the option to license the system, sending Accelr8's stock down 30 percent.

According to Accelr8, the new evaluation agreement includes analysis of data being collected in pre-clinical and pilot studies that have been initiated at the Denver Health Medical Center, and at the Barnes-Jewish Hospital in St. Louis. In addition, it said that it will share data and materials related to its ongoing development of tests for antibiotic resistance detection.

"Unlike other new technologies that only identify organisms, or only detect two or three resistance types, our system detects all of the organisms and resistance types that most often cause therapy to fail," Accelr8 President David Howson said in a statement. "We will now advance our tests over the next eight months to detect highly threatening new types of resistance that defeat standard laboratory tests. These tests use sophisticated analyses that are also valuable for new drug development."

In early Thursday afternoon trade on the American Stock Exchange, shares of Accelr8 were up 13 percent at $1.28.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.